TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02014103

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus, Mylan
Description: Administration of each formulation will be determined by sequence.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus, Mylan
Description: Administration of each formulation will be determined by sequence.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus, Mylan
Description: Administration of each formulation will be determined by sequence.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus, Mylan
Description: Administration of each formulation will be determined by sequence.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus, Mylan
Description: Administration of each formulation will be determined by sequence.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus, Mylan
Description: Administration of each formulation will be determined by sequence.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus, Accord
Description: Administration of each formulation will be determined by sequence.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus, Accord
Description: Administration of each formulation will be determined by sequence.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus, Accord
Description: Administration of each formulation will be determined by sequence.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus, Accord
Description: Administration of each formulation will be determined by sequence.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus, Accord
Description: Administration of each formulation will be determined by sequence.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus, Accord
Description: Administration of each formulation will be determined by sequence.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus, Pancea Biotech Limited
Description: Administration of each formulation will be determined by sequence.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus, Pancea Biotech Limited
Description: Administration of each formulation will be determined by sequence.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus, Pancea Biotech Limited
Description: Administration of each formulation will be determined by sequence.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus, Pancea Biotech Limited
Description: Administration of each formulation will be determined by sequence.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus, Pancea Biotech Limited
Description: Administration of each formulation will be determined by sequence.
Study: NCT04401605

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fermented Food-supplemented Diet
Description: Fermented foods include Kimchi, Sauerkraut, Yoghurt, Kefir and more.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Regular Diet
Description: No change in diet.
Study: NCT04109456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN10018
Description: 100 mg or 50mg, orally once daily continuously;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN10018
Description: 100 mg or 50mg, orally once daily continuously;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN10018
Description: 100 mg or 50mg, orally once daily continuously;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: 60mg , orally once daily from day 1 to day 21 in a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: 60mg , orally once daily from day 1 to day 21 in a 28-day cycle
Study: NCT02014103

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus, Pancea Biotech Limited
Description: Administration of each formulation will be determined by sequence.
Study: NCT01793129

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hypothermia
Description: Induced Whole-body hypothermia (with a target esophageal temperature of 33.5°C) for 72 hours

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Normothermic Control
Description: Normothermic Control group (with esophageal temperature at or near 37.0°C) for 96 hours
Study: NCT04109456

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: biweekly 840 mg dose will be used in this study starting from Cycle 2.
Study: NCT03819101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Description: 100mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Description: 100mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 80 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 80 mg
Study: NCT03882788

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoflurane
Description: Isoflurane (volatile anesthesia) will be delivered at 1.5-2.0%% as required for anesthetic management.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl (high dose)
Description: Fentanyl (narcotic anesthesia) maintenance will be with fentanyl 5 mcg/kg/hr not to exceed 10 mcg/kg/hr.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl (low dose)
Description: Fentanyl (narcotic anesthesia) maintenance will be with fentanyl 2 mcg/kg/hr.
Study: NCT04621565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: No hydrocortisone or other steroids are given before, during, and after the surgery, except that patients develop postoperative adrenal insufficiency. If a patient develops postoperative adrenal insufficiency, he/she needs to receive hydrocortisone treatment (20mg at 0800 and 20mg at 1600) for one month and then check the level of morning serum cortisol to decide if it is time to start the hydrocortisone taper program.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: Hydrocortisone sodium succinate is given on the operation day (100mg at 0800 \& 100mg at 2000), the postoperative day 1 (100mg at 0800 \& 50mg at 2000), and the postoperative day 2 (25mg at 0800). Hydrocortisone (po.) is then given starting from the afternoon of postoperative day 2 (20mg at 1600 and 0800) to the end of the first postoperative week, and 20mg at 0800 during the second postoperative week. This is called the hydrocortisone taper program. If a patient develops postoperative adrenal insufficiency, he/she needs to receive hydrocortisone treatment (20mg at 0800 and 20mg at 1600) for one month and then check the level of morning serum cortisol to decide if it is time to start the hydrocortisone taper program.
Study: NCT03246984

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VasQ
Description: VasQ device implantation in patients with a new brachiocephalic or radiocephalic fistula creation.
Study: NCT04387721

Intervention type: OTHER
Intervention: Kind of trifocal IOL
Description: Patients will be divided between groups based on pre-surgery corneal astigmatism. Group FineVision is made up of patients with corneal astigmatism less than 1 D. Groups FineVision Toric is made up pf patients with corneal astigmatism more than 1.25 D

Intervention type: OTHER
Intervention: Kind of trifocal IOL
Description: Patients will be divided between groups based on pre-surgery corneal astigmatism. Group FineVision is made up of patients with corneal astigmatism less than 1 D. Groups FineVision Toric is made up pf patients with corneal astigmatism more than 1.25 D
Study: NCT03165500

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diazepam
Description: Patients' vital signs (blood pressure, heart rate and oxygen saturation) were measured and recorded after 30 minutes of oral sedation with diazepam 5mg, during the extraction procedure and 15 minutes after the extraction.~After the surgical procedure of extraction, the patients remained in recovery in the same room, being the criteria of discharge realized, from the normality of the vital signs and the response to the verbal commands, with the patient responsive and lucid.
Study: NCT03803761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Given IV
Study: NCT03165500

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diazepam
Description: Patients' vital signs (blood pressure, heart rate and oxygen saturation) were measured and recorded after 30 minutes of oral sedation with diazepam 5mg, during the extraction procedure and 15 minutes after the extraction.~After the surgical procedure of extraction, the patients remained in recovery in the same room, being the criteria of discharge realized, from the normality of the vital signs and the response to the verbal commands, with the patient responsive and lucid.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Patients' vital signs (blood pressure, heart rate, and oxygen saturation) were measured and recorded after 30 minutes of oral sedation with midazolam 7.5mg during the extraction procedure and 15 minutes after the extraction.~After the surgical procedure of extraction, the patients remained in recovery in the same room, being the criteria of discharge realized, from the normality of the vital signs and the response to the verbal commands, with the patient responsive and lucid.
Study: NCT03803761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Given IM
Study: NCT05029076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide injection
Description: Human glucagon-like peptides-1 analogue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide injection
Description: Human glucagon-like peptides-1 analogue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Victoza
Description: Human glucagon-like peptides-1 analogue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Victoza
Description: Human glucagon-like peptides-1 analogue
Study: NCT04366986

Intervention type: OTHER
Intervention: Tested for SARS-CoV-2 (regardless of the result)
Description: This is an observational study with no intervention

Intervention type: OTHER
Intervention: Tested for SARS-CoV-2 (regardless of the result)
Description: This is an observational study with no intervention

Intervention type: OTHER
Intervention: Clinical diagnosis of COVID-19 by a health care professional
Description: This is an observational study with no intervention

Intervention type: OTHER
Intervention: Clinical diagnosis of COVID-19 by a health care professional
Description: This is an observational study with no intervention
Study: NCT03904446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylergonovine
Description: 0.2 mg of intramuscular methylergonovine at the time of cesarean section following standard IV oxytocin infusion.
Study: NCT03165500

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Patients' vital signs (blood pressure, heart rate, and oxygen saturation) were measured and recorded after 30 minutes of oral sedation with midazolam 7.5mg during the extraction procedure and 15 minutes after the extraction.~After the surgical procedure of extraction, the patients remained in recovery in the same room, being the criteria of discharge realized, from the normality of the vital signs and the response to the verbal commands, with the patient responsive and lucid.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrous Oxide + Oxygen Gas
Description: Patients' vital signs (blood pressure, heart rate, and oxygen saturation) were measured and recorded after 30 minutes of sedation Inhalation with the mixture of 40% of nitrou oxide and 60% of oxygen, during the exodontia procedure and 15 minutes later.~After the surgical procedure of extraction, the patients remained in recovery in the same room, being the discharge criteria performed, from the normality of the vital signs and the response to the verbal commands, with the patient responsive and lucid, and after the accomplishment of the test developed by Trieger et al.,(1971).
Study: NCT03904446

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline (placebo)
Description: 1 ml of normal saline intramuscular at the time of cesarean section following standard IV oxytocin infusion
Study: NCT03797716

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Little Journey app
Description: The Little Journey app allows children to explore 360-degree hospital environments familiarising and desensitising them to areas and staff they'll see on the day of surgery. Children can visit the day case ward, anaesthetic and recovery rooms where their operation will occur -all while feeling safe in their own home. As the child explores the three areas, they are introduced to animated characters of staff who explain what will happen, the equipment that will be used and how they might feel. Using head tracking technology, the child triggers the animated characters by looking at them; meaning they control the pace of learning and speed at which they progress. The preparatory tool follows a pre-set story-line reflecting what happens from admission to discharge on the day of surgery.
Study: NCT03640143

Intervention type: OTHER
Intervention: venous blood lead
Description: data about ve,nous blood lead
Study: NCT03165500

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrous Oxide + Oxygen Gas
Description: Patients' vital signs (blood pressure, heart rate, and oxygen saturation) were measured and recorded after 30 minutes of sedation Inhalation with the mixture of 40% of nitrou oxide and 60% of oxygen, during the exodontia procedure and 15 minutes later.~After the surgical procedure of extraction, the patients remained in recovery in the same room, being the discharge criteria performed, from the normality of the vital signs and the response to the verbal commands, with the patient responsive and lucid, and after the accomplishment of the test developed by Trieger et al.,(1971).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Third molar extraction
Description: Anxious patients in need of third molar extraction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Third molar extraction
Description: Anxious patients in need of third molar extraction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Third molar extraction
Description: Anxious patients in need of third molar extraction
Study: NCT02698787

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental sound coding strategy (FAST)
Description: Commercially available Cochlear™ Nucleus® CI24RE with Contour Advance™ Electrode or Cochlear™ Nucleus® CI512 cochlear implant with FAST sound coding strategy using crossover design in newly implanted subjects. Both groups will receive the experimental and control strategy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental sound coding strategy (FAST)
Description: Commercially available Cochlear™ Nucleus® CI24RE with Contour Advance™ Electrode or Cochlear™ Nucleus® CI512 cochlear implant with FAST sound coding strategy using crossover design in newly implanted subjects. Both groups will receive the experimental and control strategy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Commercially available ACE sound coding strategy
Description: Commercially available Cochlear™ Nucleus® CI24RE with Contour Advance™ Electrode or Cochlear™ Nucleus® CI512 cochlear implant with FAST sound coding strategy using crossover design in newly implanted subjects. Both groups will receive the experimental and control strategy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Commercially available ACE sound coding strategy
Description: Commercially available Cochlear™ Nucleus® CI24RE with Contour Advance™ Electrode or Cochlear™ Nucleus® CI512 cochlear implant with FAST sound coding strategy using crossover design in newly implanted subjects. Both groups will receive the experimental and control strategy
Study: NCT02445365

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AutoRIC device

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: AutoRIC device
Study: NCT02637674

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uterus Transplant
Study: NCT02411045

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Take and send a selfie
Description: Direction to take and send a selfie.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Take and send a selfie
Description: Direction to take and send a selfie.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Take and send a selfie
Description: Direction to take and send a selfie.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Workout gears
Description: Direction to wear workout gears.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Workout gears
Description: Direction to wear workout gears.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Direction to complete a 30 minute workout.
Study: NCT00438282

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: home visitation
Description: Home visitation from midway through pregnancy until child age 2. Group 2 is visitation by Paraprofessionals; group 3 is home visitation by Nurses.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: home visitation
Description: Home visitation from midway through pregnancy until child age 2. Group 2 is visitation by Paraprofessionals; group 3 is home visitation by Nurses.
Study: NCT04627974

Intervention type: DEVICE
Intervention: Evoke Spinal Cord Stimulation (SCS) System
Description: A spinal cord stimulation system that measures and records evoked compound action potentials (ECAPs) and automatically adjusts the stimulation current to maintain a consistent ECAP amplitude
Study: NCT02788929

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit Charge HR
Description: Patients randomized to the FitBit group will receive Fitbit Charge HR, a simple, user-friendly, wrist-worn, commercially available device which provides feedback on exercise goal adherence, in combination with the Fitbit mobile platform application.
Study: NCT04432272

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 convalescent plasma
Description: Participants will receive 1 unit of convalescent plasma procured from donors who have: 1) been symptom free for 14 days and screen negative via nasopharyngeal swab or 2) symptom free for at least 28 days or 3) individuals who have never had symptoms of COVID-19 but were found to have elevated anti-SARS-CoV-2 IgG by a serology test deemed to be of acceptable quality and fitting the current guidance by the FDA. Participants, clinicians, investigators and outcomes assessors will be blinded to the amount of anti-SARS-CoV-2 IgA and IgG present in each unit

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 convalescent plasma
Description: Participants will receive 1 unit of convalescent plasma procured from donors who have: 1) been symptom free for 14 days and screen negative via nasopharyngeal swab or 2) symptom free for at least 28 days or 3) individuals who have never had symptoms of COVID-19 but were found to have elevated anti-SARS-CoV-2 IgG by a serology test deemed to be of acceptable quality and fitting the current guidance by the FDA. Participants, clinicians, investigators and outcomes assessors will be blinded to the amount of anti-SARS-CoV-2 IgA and IgG present in each unit
Study: NCT03878342

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: two fractionation regimens will be allowed for whole-breast irradiation: 50 Gy in 25 fractions over 5 weeks or 40 Gy in 15 fractions over 3 weeks. The delivery of an additional dose to the tumour bed (boost) will be at the referring physician discretion, according to the guidelines

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Radiotherapy
Description: No Irradiation- Active surveillance
Study: NCT00982228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: Injected subcutaneously as mealtime insulin. Dose was individually adjusted.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Injected subcutaneously as mealtime insulin. Dose was individually adjusted.
Study: NCT03772678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LSALT peptide
Description: novel 16 amino acid peptide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LSALT peptide
Description: novel 16 amino acid peptide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LSALT peptide
Description: novel 16 amino acid peptide

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Saline
Description: saline
Study: NCT03104374

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-494
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-494
Description: Oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ABT-494
Description: Oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ABT-494
Description: Oral tablet
Study: NCT03301506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seladelpar 5 mg Capsule
Description: Subjects will be assigned to a treatment group if tolerability issues noted in the previous study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seladelpar 10 mg Capsule
Description: Subjects will be assigned to a treatment group unless there are tolerability issues.
Study: NCT01612949

Intervention type: OTHER
Intervention: photographing head and neck
Description: Taking three photographs of head and neck-one photograph from front, one from left and one fron right. The photographs are analyzed by facial structure software to create face model.

Intervention type: OTHER
Intervention: photographing head and neck
Description: Taking three photographs of head and neck-one photograph from front, one from left and one fron right. The photographs are analyzed by facial structure software to create face model.

Intervention type: OTHER
Intervention: photographing head and neck
Description: Taking three photographs of head and neck-one photograph from front, one from left and one fron right. The photographs are analyzed by facial structure software to create face model.
Study: NCT02112734

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: identical placebo daily
Study: NCT01612949

Intervention type: OTHER
Intervention: photographing head and neck
Description: Taking three photographs of head and neck-one photograph from front, one from left and one fron right. The photographs are analyzed by facial structure software to create face model.

Intervention type: OTHER
Intervention: photographing head and neck
Description: Taking three photographs of head and neck-one photograph from front, one from left and one fron right. The photographs are analyzed by facial structure software to create face model.